Merck & Co Inc
NYSE: MRK
$100.73
-$0.92 (-0.9%)
Closing Price on November 6, 2024
MRK Articles
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
As of the most recently reported period, short sellers favored Apple, Microsoft and Intel above all other Dow stocks.
Published:
Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a few of...
Published:
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Despite the never-ending election cycle, there actually is a clear path for the Dow to hit 30,000 as soon as early 2020, if only a few things come to fruition. There does not even have to be a big...
Published:
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
With markets at all-time highs, it's important to consider the winners and losers. In this case, many stocks in the Dow are still holding the index back from even stronger gains.
Published:
Last Updated:
Shares of Merck and Pfizer both got boosts after they reported their most recent quarterly results before the opening bell Tuesday.
Published:
Last Updated:
Merck and Pfizer are set to report their most recent quarterly results before the opening bell tomorrow. Pfizer is one of the most shorted of all Dow stocks.
Published:
Last Updated:
Six of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.
Published:
Last Updated:
The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Published:
Last Updated:
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
Published:
Last Updated:
The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
Merck has just announced that the FDA has accepted a couple new drug applications for review, including for a treatment for Clostridium difficile infections in children.
Published:
Last Updated: